We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen published positive results from a Phase III trial comparing Prolia (denosumab) with risedronate in patients receiving oral glucocorticoid therapy. The study met all primary and secondary endpoints at 12 months. Read More
Tonix Pharmaceuticals reported that the FDA has accepted the company’s proposed Phase III studies and planned NDA data package, following an end-of-Phase II meeting on its sublingual tablet for the treatment of post-traumatic stress disorder, TNX-102 SL. Read More
Drug sponsors that have falsified data will face three years of probation before being allowed to refile marketing applications, the Chinese FDA says. Read More
A Phase III trial of the flutiform inhaler did not meet its primary endpoint of demonstrating statistically significant superiority in the reduction of annualized rates of moderate and severe exacerbations of chronic obstructive pulmonary disease, when compared to mono-component long-acting β2-agonist treatment alone. Read More
The number of cardiovascular drugs entering the clinical development pipeline has been declining since 1990, according to a study evaluating public data from over 4,000 trials. The decline was seen across Phase I, II, and III clinical trials. Read More
Juno Therapeutics has been sued in a class-action lawsuit alleging that the company violated federal securities law by failing to disclose a death during a clinical trial. Read More